Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes
By D. Rozema, D. Lewis, Darren H. Wakefield, So C Wong, Jason J. Klein, P. Roesch, Stéphanie Bertin, Tom W. Reppen, Qili Chu, A. Blokhin and 2 more. Proceedings of the National Academy of Sciences of the United States of America, 2007
640 citations recorded by the source corpus.
Subfields: Cancer Research, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/c73bb6ba08b1f09cf73b0621e180b0c2d043a8c2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Molecular Biology
- Daniel G. Anderson
- Robert Langer
- Aaron D Springer
- S. Dowdy
- R. Juliano
- G. Shapiro
- Kathryn A. Whitehead
- O. Farokhzad
Citations in the corpus
- GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics (2018, methodology): “The first generation was a dynamic polyconjugate (DPC) that utilized an endosomolytic peptide (butyl and amino vinyl ether, PBAVE, or melittin) masked with GalNAc through a pH sensitive carboxy dimethyl maleic anhydride linkage [114,115].”
- First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. (2013, background): “Various nanoparticle formulations have been evaluated for their ability to silence targets in vivo (6-10); among these, lipid nanoparticles (LNPs) have been shown to be highly effective in delivering siRNAs to the liver and silencing a number of different hepatocyte gene targets across multiple spec”
- Knocking down barriers: advances in siRNA delivery (2009, background): “Analyses of serum liver enzyme and cytokine levels in treated mice indicated that siRNA complexes formed with this synthetic polymer were well tolerated 101 .”
- Breaking down the barriers: siRNA delivery and endosome escape (2010, background): “This is aptly demonstrated by the dynamic polyconjugate system developed by Rozema and colleagues, with which they achieved siRNA-mediated silencing specifically in hepatocytes in vivo (Rozema et al., 2007) (Fig.”
- The delivery of therapeutic oligonucleotides (2016, background): “In the original conception these were comprised of a polymer with inherent endosome destabilizing properties linked simultaneously to a PEG shield, a carbohydrate ligand targeting the ASGPR and siRNA (300).”